AVTR earnings analysis
What we found in AVTR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Avantor delivered Q2 sales of $1.6923 billion, up 0.5% year over year and ahead of consensus, with VWR Distribution & Services returning to 1.7% organic growth. However, consolidated organic sales fell 0.4%, gross margin contracted 120 bps to 31.7%, and GAAP diluted EPS declined to $0.06 from $0.09 a year ago; EPS was flat sequentially versus Q1 2026. Liquidity is solid at $1.6866 billion, but the newly disclosed VWR Distribution goodwill sensitivity—only a 5.5% fair-value cushion—is a material balance-sheet risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue exceeded consensus and grew sequentially
- Q2 net sales were $1.6923 billion, up $8.9 million (0.5%) from $1.6834 billion a year earlier and above the $1.6091 billion consensus estimate. Revenue also rose from $1.58 billion in Q1 2026.
- VWR returned to organic growth
- VWR Distribution & Services grew $33.0 million, or 2.7%, to $1.2405 billion; its $20.0 million, or 1.7%, organic increase was driven by controlled-environment consumables and specialty procurement.
- Positive cash generation despite weaker earnings
- Operating cash flow totaled $236.9 million for the first six months, while free cash flow was $168.0 million after $71.1 million of capital expenditures. Capex equaled approximately 2.2% of $3.2737 billion of six-month sales.
- Liquidity remains substantial
- Liquidity was $1.6866 billion at June 30, comprising $306.8 million of cash and $1.3798 billion of unused revolver capacity. Required term-loan payments over the next 12 months are $30.8 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Margin compression drove lower GAAP earnings
- Gross margin fell 120 bps year over year to 31.7%, while operating margin declined 50 bps to 7.2%, due to unfavorable mix, inflationary pressures and lower sales volumes. GAAP net income dropped $26.6 million to $38.1 million and diluted EPS was $0.06 versus $0.09 a year earlier.
- Bioscience weakness offsets VWR improvement
- Bioscience & Medtech Products revenue declined $24.1 million (5.1%) to $451.8 million, including a $26.8 million (5.6%) organic decline, led by lower Fluid Handling and NuSil volumes.
- New VWR goodwill-impairment risk factor
- The filing adds a risk factor that VWR Distribution is at risk of goodwill impairment: at March 31 its fair value exceeded carrying value by only approximately 5.5%, with approximately $2.8 billion of goodwill allocated to the unit. A further deterioration could produce a material non-cash charge.
- Working capital and capex reduced cash flow
- Six-month operating cash flow declined $26.8 million to $236.9 million as working-capital changes consumed $103.6 million, versus $58.0 million a year ago. Free cash flow fell $39.5 million to $168.0 million as capex increased $13.5 million to $71.1 million.
- Underlying profitability remained under pressure
- Adjusted EBITDA declined $25.5 million (9.1%) to $254.3 million and its margin contracted 160 bps to 15.0%. Restructuring, severance and related impairment charges were $24.0 million in the quarter.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.06
- Gross margin
- 31.7%
- Operating margin
- 7.2%
- Segment
- Bioscience & Medtech Products: $451.8 million revenue, down $24.1 million (5.1%) year over year; organic sales down $26.8 million (5.6%).
- Segment
- VWR Distribution & Services: $1.2405 billion revenue, up $33.0 million (2.7%) year over year; organic sales up $20.0 million (1.7%).
What they said about what is next.
The 10-Q MD&A does not provide quantitative FY2026 revenue or EPS guidance; outlook was deferred to earnings communications outside this filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 29, 2026
- Avantor, Inc. reported Q1 2026 net sales of $1,581.4 million, flat year-over-year, with diluted GAAP EPS dropping to $0.06, missing consensus expectations of $0.16. The company noted ongoing headwinds from inflation and…
- 10-K · February 11, 2026
- Avantor's 2025 10-K emphasizes a recurring, digital-first distribution and specialty-manufacturing model ("more than 85% of our net sales" recurring; "approximately 80% of our transactions came from our digital channels…
- 10-K · February 14, 2024
- Avantor emphasizes a customer-centric strategy serving biopharma, healthcare, education & government and advanced technologies from discovery to delivery, supported by a broad portfolio and global supply chain. The…
- 10-Q · July 28, 2023
- Avantor reported Q2 2023 revenue of $1,743.9 million, down versus Q2 2022 ($1,910.5 million). The company booked a $160.8 million impairment (Ritter) that depressed operating income to $71.7 million and produced a Q2…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AVTR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever